KalVista Pharmaceuticals (KALV) Capital Expenditures (QoQ) (2014 - 2025)
KalVista Pharmaceuticals (KALV) Capital Expenditures (QoQ) (2014 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 67.63% |
| Oct 31, 2024 | 1.56% |
| Jul 31, 2024 | 125.40% |
| Apr 30, 2024 | -188.11% |
| Jan 31, 2024 | 14,200.00% |
| Oct 31, 2023 | -66.67% |
| Jul 31, 2023 | -91.30% |
| Apr 30, 2023 | 360.00% |
| Jan 31, 2023 | -92.19% |
| Oct 31, 2022 | -79.13% |
| Jul 31, 2022 | 969.77% |
| Apr 30, 2022 | -57.43% |
| Jan 31, 2022 | -43.26% |
| Oct 31, 2021 | 24.04% |
| Jul 31, 2021 | 769.70% |
| Apr 30, 2021 | 135.71% |
| Jan 31, 2021 | 7.69% |
| Oct 31, 2020 | -40.91% |
| Jul 31, 2020 | 175.00% |
| Oct 31, 2019 | 16.33% |